
Resources
-
Global Regulatory Requirements for Stability: It’s Not Such a Small World After All
Speaker Presentation St. Charles Amy, Pfizer Inc., 2020
-
Forced Degradation Studies in Support of Product Development and Registration
Speaker Presentation Krug Elisabeth, Eli Lilly and Company, 2020
-
Use and Interpretation of Accelerated Stability Studies
Speaker Presentation Krause Philip, CBER, FDA, 2020
-
A Regulatory Perspective on Stability Studies Supporting Comparability of Therapeutic Protein Products
Speaker Presentation Damdinsuren Bazarragchaa, CDER, FDA, 2020
-
The Predictive Value of Accelerated & Forced Degradation Data: A Case Study
Speaker Presentation Smith Dean, Health Canada, 2020
-
Demonstration of Comparability in Accelerated or Stressed Stability Studies Using Graphical and Statistical Methods
Speaker Presentation Burdick Richard, Burdick Statistical Consulting LLC., 2020
-
Providing the Right Data at the Right Time: Stability Strategies to Support Analytical Comparability
Speaker Presentation Rieder Noel, Amgen Inc., 2020
-
Control Strategies for Particles Arising from HCPmediated Degradation of Polysorbate: A Regulatory Perspective
Speaker Presentation Russell Paula, Health Canada, 2020
-
Polysorbate Degradation Case Studies: Characterization, Mechanism Elucidation, Mitigation Measures and Implications for Control Strategy
Speaker Presentation Koulov Atanas, Lonza AG, 2020
-
Excipients and Biotechnology Product Quality Attributes: a Regulator’s Perspective on Reducing the Interfacial Tension
Speaker Presentation Rao Ashutosh, CDER, FDA, 2020
-
New Aspects on the Degradation Mechanisms of Polysorbate: Complex Reaction Pathways of a Complex Surfactant
Speaker Presentation Schöneich Christian, University of Kansas, 2020
-
Mechanisms of Surfactant Degradation: Focus on Enzymatic Hydrolysis
Speaker Presentation Huang Lihua, Eli Lilly and Company, 2020
-
A Multi-company Assessment of Submicron Particle Levels in Biotechnology-derived Protein Products
Speaker Presentation Hubert Mario, Bristol-Myers Squibb Company, 2020
-
Visible Particles from Polysorbate Degradation
Speaker Presentation Nikels Felix, Boehringer Ingelheim Pharma GmbH & Co. KG, 2020
-
Phase Appropriate Expectations for Analytical Methods and Process Validation for Expedited Programs: A Regulatory Perspective
Speaker Presentation Powdrill Megan, Health Canada, 2020
-
Merck's Approaches and Challenges for Implementation of Phase-Appropriate GMP Continuum
Speaker Presentation Mabe Todd, Akouos Inc., 2020
-
Validation and Implementation of an Automated Colony Counter for Product Testing in Biopharmaceutical Manufacturing
Speaker Presentation Deutschmann Sven, Roche Siagnostics GmbH, 2020
-
Expedited Programs: Phase Appropriate Regulatory Expectations for Microbial Control and Sterility Assurance
Speaker Presentation Hughes Patricia, CDER, FDA, 2020
-
Taking Stability Off the Critical Path of Product Development
Speaker Presentation Lennard Andrew, Amgen Limited, 2020
-
Specific Regulatory Strategies for Process Validation for Biologics
Speaker Presentation Wilkinson Diane, AstraZeneca, 2020